AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer
Yûichi Murakami(Meijo University), Mayumi Ono(Chiba University Hospital)
Cited by 24
Related Papers
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation
|Molecular Cancer Therapeutics|2004|309
Infiltration of COX-2–expressing macrophages is a prerequisite for IL-1β–induced neovascularization and tumor growth
|Journal of Clinical Investigation|2005|284
Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages
|PLoS ONE|2014|99